NASDAQ:AMRN - Amarin Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$17.37 -0.14 (-0.80 %)
(As of 03/26/2019 10:07 AM ET)
Previous Close$17.51
Today's Range$17.32 - $17.78
52-Week Range$2.35 - $23.33
Volume12,330 shs
Average Volume8.46 million shs
Market Capitalization$5.61 billion
P/E Ratio-45.10
Dividend YieldN/A
Beta1.29
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.21 million
Book Value$0.40 per share

Profitability

Net Income$-116,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$5.61 billion
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings results on Wednesday, February, 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $77.30 million for the quarter, compared to the consensus estimate of $73.87 million. The firm's revenue for the quarter was up 43.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.08) earnings per share. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Amarin.

What guidance has Amarin issued on next quarter's earnings?

Amarin issued an update on its FY 2019 earnings guidance on Wednesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $350-350 million, compared to the consensus revenue estimate of $352.7 million.

What price target have analysts set for AMRN?

6 brokerages have issued twelve-month price objectives for Amarin's stock. Their forecasts range from $20.00 to $51.00. On average, they expect Amarin's stock price to reach $32.1667 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. Stifel Nicolaus analysts commented, "We believe Vascepa’s REDUCE-IT study results are impressive and based on our physician survey, will most certainly lead to robust growth, likely above management’s 2019 guidance. With that said, our call here does run counter to the prevailing sentiment that AMRN will be acquired in the near term and believe the outcome of an advisory committee discussing the REDUCE-IT results and controversies around them will be needed before a takeout can occur. Our diligence with regulatory experts get us comfortable with an FDA approval for a Vascepa label expansion to include reduction in CV risk based on the REDUCE-IT results in early 2020, which should effectively increase its addressable market size by a factor of 20. From a valuation perspective, we use a blended methodology given the takeout premium in the stock and arrive at a $27 target price." (3/21/2019)
  • 2. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (1/23/2019)
  • 3. Cantor Fitzgerald analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (12/14/2018)
  • 4. HC Wainwright analysts commented, "We believe that beyond the topline of 25% reduction of MACE score, the robustness of the data is highlighted by the consistency across pre-specified analyses. A key secondary composite, namely 3-point MACE score (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), which assesses the major CV events (and reflects the most important clinical relevance), showed an even higher reduction of risks at 26% compared to placebo. The clinical benefits as measured by the primary endpoint of MACE score and the key secondary 3-point MACE score are observed across subgroups (statistically significant in the vast majority of the subgroups), which speaks to the validity and robustness of the data." (11/12/2018)

Has Amarin been receiving favorable news coverage?

Press coverage about AMRN stock has trended somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amarin earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Are investors shorting Amarin?

Amarin saw a increase in short interest in February. As of February 28th, there was short interest totalling 17,514,524 shares, an increase of 13.6% from the February 15th total of 15,412,976 shares. Based on an average trading volume of 10,037,142 shares, the days-to-cover ratio is presently 1.7 days. Currently, 6.1% of the shares of the stock are sold short. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Exelixis (EXEL), Alibaba Group (BABA), Netflix (NFLX), Sarepta Therapeutics (SRPT), Bank of America (BAC) and AcelRx Pharmaceuticals (ACRX).

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Pres, CEO & Director (Age 58)
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 48)
  • Dr. Steven B. Ketchum, Pres of R&D, Sr. VP and Chief Scientific Officer (Age 54)
  • Mr. Joseph T. Kennedy, Exec. VP, Gen. Counsel & Strategic Initiatives (Age 51)
  • Ms. Elisabeth Schwartz, Sr. Director of Investor Relations

Who are Amarin's major shareholders?

Amarin's stock is owned by many different of institutional and retail investors. Top institutional shareholders include venBio Select Advisor LLC (1.73%), Perceptive Advisors LLC (1.51%), BlackRock Inc. (1.04%), Eversept Partners LP (0.39%), Opaleye Management Inc. (0.39%) and Two Sigma Investments LP (0.38%). Company insiders that own Amarin stock include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Geode Capital Management LLC, Stonepine Capital Management LLC, Opaleye Management Inc., Two Sigma Advisers LP, Frontier Capital Management Co. LLC, GSA Capital Partners LLP and Bank of America Corp DE. Company insiders that have sold Amarin company stock in the last year include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, venBio Select Advisor LLC, Two Sigma Investments LP, Elk Creek Partners LLC, Gladstone Capital Management LLP, Eversept Partners LP, Chartwell Investment Partners LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $17.51.

How big of a company is Amarin?

Amarin has a market capitalization of $5.65 billion and generates $229.21 million in revenue each year. The biopharmaceutical company earns $-116,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  614 (Vote Outperform)
Underperform Votes:  372 (Vote Underperform)
Total Votes:  986
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Featured Article: Return On Assets

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel